3Felix CA,Walker AH,Lange BJ,et al.Association of CYP3A4 genotype with treatment-related leukemia [J].Proc Natl Acad Sci,1998,95(22):13176
4Gonzalez FJ,Rade KC,Daniel W,et al.Characterization of the common genetic defect in humans deficient in debrisoquine metabolism[J].Nature,1998,331(6155):442
5Enans WE,Mcleod HL.Pharmacogenetics-drug disposition,drug target,and side effects[J].N Eng1 J Med,2003,348(6):538
6Richard E,Pratt,Victor J.Pharmacogenetics and hypertension concepts,potentials,and opportunities[J].Hypertension,1999,33:238
7Bond C,Laforge KS,Tian M,et al.Single-nucleotide polymorphism in the human α-opium receptor gene alters endorphin binding and activity possible implications for opiate addiction[J].Proc Nat1 Acad Sci USA,1998,95:9608
8March R.Pharmacogenetics:the genomics of drug response[J].Yeast,2000,17(1):16
6[5]Aris P.Pharmacogenomics and diagnostics[J].Nat Biotechnol，1998，16(8):791.
7[6]Shi MM，Bleavins MR,De la iglesia FA.Technologies for detecting genetic polymorphism in pharmacogenomics[J].Mol Diagn,1999,4(4):343.
8[7]Hess P,Cooper D.Impact of pharmacogenomics on the clinical laboratory[J].Mol Diagn,1999,4(4):289.
9[8]Dubinsky MC,Lamothe S,Yang HY,et al.Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in flammatory bowel diseasa.Gastroenterology,2000,118(4):705.
10[9]Garry PJ,Baumgartner RN,Brodie SG,et al.Estrogen replacement therapy,serum lipids,and polymorphism of the Apolipoprotein E gene[J].Clin Chem,1999,45(8):1 214.
